Ann Marie Schmidt MD and Ravi Ramasamy, PhD were awarded a Collaborative Interdisciplinary Team Science in NIDDK Research Areas (R24) grant from the NIH/NIDDK. In collaboration with Dr. Alex Shekhtman at the State University of New York at Albany, Columbia University and Albany Molecular Research Inc. (AMRI), the research will focus on developing novel therapies and target engagement biomarkers for the treatment of diabetic complications. Participation of colleagues in NYU's Office of Translational Alliance (OTA) (Drs. Robert Scheider, Nadim Shohdy and Sadhana Chitale) rounds out the team of investigators in this mission.
Dr. Ramasamy has been granted tenure by the University. Effective July 1, 2014.
Fei Song, MD is the Diabetes Research Program Researcher of the Month.
Ravi Ramasamy, PhD was awarded a shared instrumentation grant from the National Institutes of Health for the acquisition of Seahorse system. This state of the art automated system will be used to assess cellular respiration, mitochondrial properties, and glycolysis in real time. Seahorse system will be placed within the Research Support Core at NYULMC.
On May 7, 2013, the Department of Medicine held its 12th Annual Research Day. Several members of the Diabetes Research Program participated in this event.<<more>>
The Diabetes Research Program and NYU's Initiative in Data Science and Statistics were awarded a research grant from Independence Blue Cross. The goal of this collaboration is twofold; detect undiagnosed diabetes cases and predict potential cases of the disease. <<more>>
Ann Marie Schmidt, MD and Ravi Ramasamy, PhD were awarded a grant from the NYU Abu Dhabi Institute. In collaboration with the NYU Abu Dhabi Public Health Research Institute, the project will examine the growing obesity and diabetes epidemic in Abu Dhabi.
Ravi Ramasamy, PhD and Gabrielle Gold-von Simson, MD were awarded a multi-PI R25 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIH). The grant titled “A New Era of Targeted Drug Discovery and the Path of Development” will enable NYU School of Medicine to offer a modern and innovative NIDDK-relevant course series with a multidisciplinary curriculum. This series of courses and seminars is intended to delineate how the very nature of drug development impinges upon the scientific understanding of a drug and its target(s) from its genesis at the bench through post-marketing experience and back again. The ultimate goal of this funded program is to stimulate new investigators across diverse disciplines to the field of drug development with a focus on diabetes, diabetic complications and obesity.
In November 2011 we published the results of our collaborative studies with Columbia University and Memorial Sloan Kettering on RAGE and massive liver resection. Our results crystallize the concept that RAGE is not primarily involved in innate immune responses; rather, RAGE perpetuates inflammatory signals that lead to excessive cellular and tissue damage. Our findings suggest that blockade of RAGE may be an effective strategy for curtailing adverse inflammation in extensive liver damage. <<more>>